Rare De Novo Copy Number Variants in Patients with Congenital Pulmonary Atresia

Li Xie¹, Jin-Lan Chen¹, Wei-Zhi Zhang¹, Shou-Zheng Wang¹, Tian-Li Zhao¹, Can Huang¹, Jian Wang¹,², Jin-Fu Yang¹,², Yi-Feng Yang¹,², Zhi-Ping Tan¹,²

¹Department of Cardiothoracic Surgery, the Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China, ²The Clinical Center for Gene Diagnosis and Therapy of the State Key Laboratory of Medical Genetics, the Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China

Abstract

**Background:** Ongoing studies using genomic microarrays and next-generation sequencing have demonstrated that the genetic contributions to cardiovascular diseases have been significantly ignored in the past. The aim of this study was to identify rare copy number variants in individuals with congenital pulmonary atresia (PA).

**Methods and Results:** Based on the hypothesis that rare structural variants encompassing key genes play an important role in heart development in PA patients, we performed high-resolution genome-wide microarrays for copy number variations (CNVs) in 82 PA patient-parent trios and 189 controls with an Illumina SNP array platform. CNVs were identified in 17/82 patients (20.7%), and eight of these CNVs (9.8%) are considered potentially pathogenic. Five de novo CNVs occurred at two known congenital heart disease (CHD) loci (16p13.1 and 22q11.2). Two de novo CNVs that may affect folate and vitamin B12 metabolism were identified for the first time. A de novo 1-Mb deletion at 17p13.2 may represent a rare genomic disorder that involves mild intellectual disability and associated facial features.

**Conclusions:** Rare CNVs contribute to the pathogenesis of PA (9.8%), suggesting that the causes of PA are heterogeneous and pleiotropic. Together with previous data from animal models, our results might help identify a link between CHD and folate-mediated one-carbon metabolism (FOCM). With the accumulation of high-resolution SNP array data, these previously undescribed rare CNVs may help reveal critical gene(s) in CHD and may provide novel insights about CHD pathogenesis.

Introduction

Congenital heart diseases (CHDs) are the most common birth defects and cause significant morbidity and mortality in children worldwide. The incidence of CHD has been estimated at approximately seven per 1000 newborns, which has not changed over the past several decades [1]. Pulmonary atresia (PA) is rare and is one of the most severe cardiac malformations. This condition is characterized by a completely atretic pulmonary valve and the obstruction of blood outflow from the heart to the lungs [2]. PA only accounts for 1% of all CHDs; however, despite tremendous advances in the medical care of CHD patients, PA remains a leading cause of neonatal loss, especially in infants diagnosed with PA with an intact ventricular septum (PA-IVS) [3,4].

Rare genetic variations have largely been ignored in the study of complex genetic disorders and other phenotypes [5–7], such as cardiovascular diseases, despite the fact that the genetic cause of these diseases remains largely unknown. Recent advances in microarray-based genome profiling analysis have greatly facilitated the delineation of rare de novo copy-number variations (CNVs) that underlie cardiovascular diseases. For example, rare CNVs have become a focus in the exploration of the genetic contributions to tetralogy of Fallot (TOF) [7–10], syndromic CHD [11,12], thoracic aortic aneurysms and dissections [13], and long QT syndrome [14].

More than 1700 genes are thought to play integral roles in mouse cardiac development, and homologs of these genes might be candidate genes involved in CHD in humans [15]. However, only a small number of these genes have been found to carry mutations associated with CHD in humans [16–18]. One plausible explanation is that mutations in critical genes result in severe birth defects or are lethal to the fetus; thus, these mutations are not found in living individuals with less severe defects [19]. We hypothesized that we would more likely discover rare structural variants that encompass key genes involved in heart development in PA than in TOF or less severe types of CHD. By focusing on one of the most severe types of CHD, PA, and by genotyping 82 patient-parent trios with an Illumina SNP array platform, we detected three previously undescribed genomic lesions: 5q14.1dup (DHFR), 10p13dup (CUBN) and 17p13.2del (CAMTA2).
## Methods and Materials

### Patient Selection

This study was approved by the Review Board of the Second Xiangya Hospital of the Central South University. All probands and their relatives who participated in the study gave written informed consent. All participants consented to this study, and blood samples were collected after receiving written informed consent from the patient’s parent or guardian on behalf of the children enrolled. After the screening of more than 6950 patients under age 14 with CHD who were admitted to the Department of Pediatric Cardiology at the Second Xiangya Hospital of Central South University, 82 PA patients and their unaffected parents were recruited to this study and began the Cardiac Biospecimen Collection procedure. The patient cohort included 30 males and 52 females from South Central China, with a mean age of 3 years old (range of 10 days to 14 years old). The whole blood samples were collected and stored in the Cardiac Genomic Bank of the Second Xiangya Hospital of the Central South University.

Twin studies with congenital malformations are one of the commonly accepted methods for the systematic study of human genetics because twins help elucidate the relationships between genetics, epigenetics, and the environment. Three twin pairs, including two pairs of monozygotic twins and one dizygotic twin pair, were included in this study (Table 1).

Each PA patient and their unaffected parents were assessed using echocardiography, and the diagnosis of PA was further confirmed at the time of surgery. A total of 189 ethnically matched control subjects were also evaluated by echocardiography to exclude CHD.

### Cytogenetic Analysis

The peripheral blood samples from the PA patients and the parents of those patients with potentially pathogenic CNVs were collected from each individual and followed by chromosome analysis using conventional G-banding techniques at the 550 band level. A lymphocyte culture was performed for all samples according to a standard cytogenetic protocol.

### DNA Extraction

Genomic DNA was prepared from peripheral blood using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) on the QIAcube automated DNA extraction robot (Qiagen, Hilden, Germany).

### CNV Identification and Novelty Assessment

Genomic DNA samples from the patients and parents were adjusted to a final concentration of 50 ng/μl. The Human660W-Quad/HumanOmni1-Quad BeadChips (Illumina Inc, San Diego, USA) and Illumina BeadScan genotyping system (Beadstation Scanner) were employed to obtain the signal intensities of SNP probes. The Human660W-Quad contains nearly 660,000 SNP markers, and the HumanOmni1-Quad Beadchip contains over 1.1 million loci, including markers derived from the three HapMap studies, the 1000 Genomes Project and recently published studies [20]. GenomeStudio V2011 software was used to analyze the genotypes (human genome build 37/Hg19 was used for analysis), and the data were further analyzed with a program that included Illumina cnvPartition (V2.3.4) to call the CNVs. To assess the novelty of high-confidence CNVs, we compared their coordinates to known CNVs in the database of Genomic Variants and DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources). Our raw data for public release have been approved and assigned GEO accession numbers GSE56422 study at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE56422. The entries are scheduled to be released on Apr 02, 2014.

### Real-time Quantitative PCR Validation

For eight potentially pathogenic CNVs, at least two primer sets were designed within the boundaries of the CNV region (primers are listed in the Table S1). Real-time quantitative PCR (qPCR) was performed using a 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, California) to validate variable copy numbers. PCR reactions were prepared using the SYBR Premix Ex Taq II PCR reagent kit (TaKaRa Bio, Dalian, China) according to the manufacturer’s instructions. Primer pairs were designed using the online PrimerQuest tool from Integrated DNA Technology (http://www.idtdna.com/Primerquest/Home/Index). Amplification levels were calculated using the $2^{-ΔΔCT}$ method.

### Results

Eighty-two patients with PA, including three pairs of twins, were included in this study. Among the patients, 77 PA patients with a ventricular septal defect (PA-VSD) and five PA patients with an intact ventricular septum (PA-IVS), were genotyped using SNP-based microarrays. To explore CNVs that are potentially responsible for PA and avoid overestimating the causality of CNVs, we focused on deletions/duplications (copy number 1 or 3 at the autosomes and 0 or 1 at the X chromosome in males and females, respectively) with high confidence. We identified 412 CNVs (256 copy losses and 156 copy gains) with an average of five CNVs per patient and an average length of 400,250 bp (range of 59,926–5,217,518 bp).

### Table 1. Three Chinese pair twins with pulmonary atresia and/or tetralogy of Fallot.

| Family | Case | Status        | Age | Sex | CHD types |
|--------|------|---------------|-----|-----|-----------|
| 1      | Twin A | dizygotic     | 3y  | F   | PA        |
|        | Twin B |               |     |     |           |
| 2      | Twin A | monozygotic   | 6m  | F   | PA        |
|        | Twin B |               |     |     | TOF       |
| 3      | Twin A | monozygotic   | 2y  | F   | PA        |
|        | Twin B |               |     |     | TOF       |

PA, pulmonary atresia; TOF, tetralogy of Fallot; y, years; m, month; F, female

doi:10.1371/journal.pone.0096471.t001
| Patients          | Loci     | Copy | CNV coordinates          | Size (kb) | Inheritance | Critical Genes                                                                 | Status |
|------------------|----------|------|--------------------------|-----------|-------------|--------------------------------------------------------------------------------|--------|
| 869677           | 2q37.1   | Loss | chr:2:234255714-234415570| 160       | De novo     | DGKD, USP40                                                                      | UK     |
| Family1 TwinA    | 3p26.3-p26.1 | Loss | chr:3:204652-4944387     | 4740      | Inherited   |                                                                                | UK     |
| 10p15.3-p15.1    | Gain     |     | chr:10:59083-5276600     | 5180      | Inherited   | 12 genes                                                                        | UK     |
| Family1 TwinB    | 3p26.3-p26.1 | Loss | chr:3:38411-4944387     | 4906      | Inherited   | 10 genes                                                                        | UK     |
| 10p15.3-p15.1    | Gain     |     | chr:10:103994-5276659    | 5172      | Inherited   | 12 genes                                                                        | UK     |
| 817646           | 5q13.2   | Loss | chr:5:68930217-70573127  | 1643      | De novo     | SMN1, SMN2                                                                       | UK     |
| 881678           | 5q14.1   | Gain | chr:5:75132315-79558945  | 4827      | De novo     | DHRF, DMGDH, PDE8B, AP3B, ARSB                                                  | PP     |
| 894020           | 6p21.33  | Loss | chr:6:31467185-31569111  | 102       | De novo     | NFkB1, LTA, TNF, NCR3                                                           | UK     |
| 706346           | 6p21.33  | Loss | chr:6:3146627-31570907   | 103       | De novo     | NFkB1, LTA, TNF, NCR3                                                           | UK     |
| 875001           | 9q33.3   | Gain | chr:9:12704846-12775670  | 655       | De novo     | NRG1, NRG2                                                                       | UK     |
| 765647           | 10p13    | Gain | chr:10:1683466-1705824   | 175       | De novo     | CUBN                                                                             | PP     |
| 807411           | 13q33.1  | Gain | chr:13:10290237-103345247| 443       | De novo     | FGF14                                                                            | UK     |
| 894147           | 15q26.3  | Gain | chr:15:99004156-99782996 | 779       | De novo     | IGF1R, SYNM                                                                      | UK     |
| 882624           | 16p13.1  | Gain | chr:16:15395312-16270740 | 875       | De novo     | MYH1, ABC6, NDE1                                                                 | P      |
| 791019           | 16p13.3  | Loss | chr:16:1866643-2604949   | 738       | De novo     | ABC3, TSC2, PKD1, TBC1D24                                                        | UK     |
| 827979           | 17p13.2  | Loss | chr:17:404135-5091377    | 1050      | De novo     | CAMTA2, CHRNE, GPIB, BA, ENO3                                                   | PP     |
| Family2 TwinA    | 22q11.2  | Loss | chr:22:1725869-18692668  | 1437      | De novo     | TFK1                                                                             | P      |
| 795265           | 22q11.2  | Loss | chr:22:17089407-19795050  | 2706      | De novo     | TFK1                                                                             | P      |
| 877494           | 22q11.2  | Loss | chr:22:1710316-19801287   | 2700      | De novo     | TFK1                                                                             | P      |
| 742265           | 22q11.2  | Loss | chr:22:1725869-19795050   | 2539      | De novo     | TFK1                                                                             | P      |

P, pathogenic; UK, unknown; PP, potentially pathogenic.
doi:10.1371/journal.pone.0096471.t002
To identify pathogenic CNVs that encompass possible causative genes for CHD, the genes located within the CNVs were analyzed. We identified genomic lesions in 17/82 patients (20.7%), and eight of these CNVs (9.8%) are considered potentially pathogenic. The eight pathogenic or potentially pathogenic CNVs were further validated by Real-time quantitative PCR (Primers are listed in Table S1). Five de novo CNVs occurred at two known congenital heart disease (CHD) loci (16p13.1 and 22q11.2). Three rare CNVs are previously undescribed genomic aberrations: duplication of 5q14.1 (DHFR), duplication of 10p13 (CUBN) and deletion of 17p13.2 (CAMTA2). The results of these potentially pathogenic CNVs are summarized (Table 2).

**CNVs Linked to Folate and Vitamin B12 Metabolism**

We examined whether PA-associated CNVs encompass gene(s) that related to specific genetic pathways and identified two CNVs that encompass genes associated with folate and vitamin B12 metabolism. A 5q14.1 duplication (chr5:75132315-79958945) spanned approximately 4.8 Mb and encompassed DHFR (MIM 126060) and other critical genes, such as PDE3B (MIM 603390),

![Figure 1. Rare CNVs related to folate and Vitamin B12 metabolism.](image)

(A) SNP-array shows a 4.8 Mb duplication at 5q14.1 (chr5:75132315-79958945); (B) A 175-kb duplication at 10p13 (chr10:16883466-17058324) (UCSC Genome Browser on Human GRCh37/hg19 Assembly). Log R ratio and B allele frequency are showed in the upper panel and annotated genes are listed in the lower panel. (C) Summary of Folate metabolic pathway (Methionine-Homocysteine-Folate-B12 Cycle). DHF, dihydrofolate; THF, tetrahydrofolate; DHFR, dihydrofolate reductase; MTHFR, methylenetetrahydrofolate reductase; SHMT, serine hydroxyl-methyltransferase; MAT, methionine adenosyltransferase; SAH, 5-adenosylhomocysteine; SAM, 5-adenosylmethionine; MTR, methionine synthase; PRMT, protein arginine methyltransferase; CUBN, Cubilin. Adapted from Lee et al [41].

doi:10.1371/journal.pone.0096471.g001
The other CNV was a 10p13 duplication that is 175 kb in size and affected only one gene, *CUBN* (MIM 602997) (Figure 1).

**CNVs in Twins with PA**

The patient cohort also included three pairs of twins: one pair of dizygotic twin sisters who both had PA and two monozygotic pairs who were diagnosed with PA or TOF. Identical 3p26.3-26.1 deletions and 10p15.3-p15.1 duplications were identified in the dizygotic twin sisters with PA (family 1, Figure 2). The karyotypes of the twins and their parents were normal according to traditional G-banding analysis (Figure S1). A 22q11.2 deletion (1.5 Mb) was detected in the pair of monozygotic twins from family 2 with discordant CHD subtypes, PA and TOF (Table 1).

**Other Rare de novo CNVs in PA**

Rare potentially pathogenic CNVs at 17p13.2del (chr17:4041358-5091377) were observed. The 1-Mb deletion at 17p13.2 spanned four OMIM morbid genes: *CHRNE* (MIM 100725), *GPIB1* (MIM 606672), *PEV1* (MIM 176610), and *EXO3* (MIM 131370) (Figure 3). The single occurrences of five rare CNVs that were observed (three deletions at 2q37.1, 5q13.2, and 16p13.3; and two duplications at 13q31.1 and 15q26.3) might represent benign variants (Table 2). The clinical importance of two recurrent deletions at 6p21.33 remains unknown (Figure S2).

**Discussion**

We have presented one of the largest genetic studies investigating the role of rare CNVs in the severe heart defect, PA. The data from 82 PA patient-parent trios and 189 controls were analyzed with a well-defined platform (Human660W-Quad/Omni1-Quad SNP-arrays). Copy number variations were identified in 17/82 patients (20.7%), and eight of these CNVs (9.8%) are considered pathogenic or potentially pathogenic. The overall CNV frequency in our study is consistent with that found in previous studies of isolated or syndromic CHD patients based on different microarray platforms using array comparative genome hybridization or SNP arrays [7,8,21].

Previous research suggests that the risk of CHD may be related to genetic variants in folate pathway-related genes [22–26]. However, genetic evidence is lacking [27–29]. Our study presents evidence for an association between folate-related genes and a specific subtype of CHD (PA) in humans. We have identified two potentially pathogenic CNVs linked to folate-mediated one-carbon metabolism (FOCM). One CNV is a 4.8-Mb duplication on 5q14.1 that contains *DHFR*, and another CNV is a 10p13 duplication that affects only one gene, *CUBN*. Dihydrofolate reductase (DHFR) is a key folate-metabolizing enzyme that catalyzes the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF), as well as folic acid to DHF [30]. Several groups have shown that inhibiting the expression of DHFR results in embryonic lethality in zebrafish. Interestingly, the anatomic malformations observed with PA in humans are consistent with the defects in the outflow tract in the zebrafish model [31,32]. Cubilin, encoded by *CUBN*, is a receptor expressed in the apical pole of absorptive epithelia [33], and it plays an important role in the absorption of vitamin B12 [34]. The interactions between folate, vitamin B12, and homocysteine are summarized in Figure 1C. Both potentially pathogenic CNVs are duplications,
implying that the association of CHD with these genes might be dosage-sensitive. However, the underlying molecular mechanisms linking FOCM to birth defects, such as CHD, remain unknown.

Two dizygotic twin sisters of family 1 shared an identical 3p26.3-26.1 deletion and a 10p15.3-p15.1 duplication, while the karyotypes of the twins and their parents were normal at 550 band resolution (Figure S1). The 3p26.3-p26.1 deletion spanned approximately 4.9 Mb and affected more than 10 genes, including SUMF1, ITPR1, and CRBN. The 5.1-Mb duplication at 10p15.3-p15.1 contained several disease-causing genes, such as KLF6, AKR1C2, and AKR1C4. Fine mapping of these two genomic regions (3p26.3-26.1 and 10p15.3-p15.1) revealed that the twins with PA carry a larger duplication at the terminus of chromosome 10p than their healthy mother (Figure 2B). Recently, Tremblay et al. mapped a gene associated with ventricular aneurysms and septal defects to chromosomal loci (10p15.3-p15.2) using classic familial linkage analysis [35]. This evidence collectively suggests that the 620-kb region at chromosomal 10p15.3 (chr10:103934724229) may represent a plausible CNV with causative genes for CHD.

Two other de novo CNVs, one with an 875-kb duplication at 16p13.1 (chr16:15395312-16270740) and the other with a 1-Mb deletion at the 17p13.2 locus (chr17:4041358-5091377), were found in only one individual with PA. Of the 12 genes contained in the 16p13.1 region, MYH11 has been previously associated with heart disease. Mutations in MYH11 cause thoracic aortic aneurysm/dissection, and recurrent 16p13.1 duplications confer a risk for aortic dissection [7,13,36]. The 1-Mb deletion at 17p13.2
covers a gene-rich region (with 30 annotated genes), suggesting that this CNV is potentially pathogenic. In this 17p13.2 deleted region, the gene CAMTA2, designated as calmodulin binding transcription activator 2, is part of a family of activators of the ANF promoter. Camta2 has been shown to interact with Nkx2-5 and promote cardiac hypertrophy in mice [37]. For this reason, CAMTA2 is an appropriate candidate gene for CHD that is caused by a 17p13.2 deletion disorder. The 17p13.2 deletion is rarely reported in the literature, and thus far, only two 17p13 deletions [38,39] and one 17p13 duplication [40] have been reported in patients with intellectual disability. A re-evaluation of this individual with the 17p13.2 deletion identified mild intellectual disability, hypotonia, and subtle facial features, raising the possibility of a previously unrecognized microdeletion disorder.

In summary, we identified eight rare de novo CNVs (9.0%) in patients with PA including three previously undescribed CNVs: 5q14.1dup (DHFR), 10p13dup (CUBN) and 17p13.2del (CAMTA2). Our results suggest that rare CNVs likely contribute significantly to the genetic basis of cardiovascular diseases, such as PA. Our study provides evidence for the association of CHD with FOCM. The discovery of previously undescribed rare CNVs in patients with CHD helps elucidate critical gene(s) for CHD and may provide new insights into understanding the pathogenesis of CHD.

Supporting Information

Figure S1 G-banded karyotype analysis of the twin family 1. Both individuals (Twin A and Twin B) have normal karyotypes. (TIF)

Figure S2 Illumina SNP-array result of the 6p21.33 deletions in patient 894020 and patient 706346. (TIF)

Table S1 Primers for Real-time Quantitative PCR Validation. (DOCX)

Acknowledgments

We are grateful to the patients and their parents for participating in this study. We thank Long Ma for providing critical suggestions. We are also grateful to the Illumina SNP-array platform (the State Key Laboratory of Medical Genetics of China), in particular to Qian Pan and Yi-Qiao Hu for technical support.

Author Contributions

Conceived and designed the experiments: ZPT LX YFY. Performed the experiments: LX JW JLC TLZ. Analyzed the data: ZPT LX CH SZW. Contributed reagents/materials/analysis tools: JW JFY WZZ. Wrote the paper: ZPT LX YFY.

References

1. Hoffman JL, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll Cardiol 39: 1890–1900.
2. Digilio MC, Marino B, Grazzini S, Agostino D, Giannotti A, et al. (1996) Comparison of occurrence of genetic syndromes in ventricular septal defect with pulmonic stenosis [classic tetralogy of Fallot] versus ventricular septal defect with pulmonic atresia. Am J Cardiol 77: 1375–1376.
3. Leonard H, Derrick G, O’Sullivan J, Wren C (2000) Natural and unnatural history of pulmonary atresia. Heart 84: 499–503.
4. Anzino KM, Kaczyński T, O’Carroll A, MacDonald G, Freedman RM, et al. (2006) Independent factors associated with mortality, reinvention, and achievement of complete repair in children with pulmonary atresia with ventricular septal defect. J Am Coll Cardiol 47: 1448–1456.
5. Farver RA, Heik RA, Gardner TW, Ballou F, Woodhams DE, et al. (2013) Chromosomal copy number variation, selection and uneven rates of recombination reveal cryptic genome diversity linked to pathogenicity. PLoS Genet 9: e1003702.
6. Hitz MP, Lemieux-Perreault LP, Marshall C, Ferroz-Zada Y, Davies R, et al. (2013) Rare copy number variations contribute to congenital left-sided heart disease. PLoS Genet 9: e1002903.
7. Silversides CK, Lionel AC, Costain G, Merico D, Migita O, et al. (2012) Rare copy number variation morbidity map of developmental delay. Nat Genet 43: 838–846.
8. Greenacay SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, et al. (2009) De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. PLoS Genet 5: e1000243.
9. Soemedi R, Wilson J, Bentham J, Darlay R, Topf A, et al. (2012) Contribution of Global Rare Copy-Number Variants to the Risk of Sporadic Congenital Heart Disease. Am J Hum Genet 8: 54–66.
10. Bansal V, Dorn G, Grunert M, Klaassen S, Herzer R, et al. (2014) Outlier-based identification of copy number variations using targeted resequencing in a small cohort of patients with tetralogy of fallot. PLoS One 9: e83376.
11. Cooper GM, Cole BP, Girirajan S, Rosenfeld JA, Jin L, et al. (2011) A copy number variation morpbo-distribution map of developmental delay. Nat Genet 43: 838–846.
12. Lu C, Yang YE, Yin BL, Chen JN, Huang C, et al. (2012) Microduplication of 3p25.2 encompassing RAF1 associated with congenital heart disease suggestive of Noonan syndrome. Am J Med Genet A 156A: 1918–1923.
13. Prakash SK, LeMaire SA, Guo DC, Russell L, Regalado ES, et al. (2010) Rare copy number variants disrupt genes regulating vascular smooth muscle cell adhesion and contraction in sporadic thoracic aortic aneurysms and dissections. Am J Hum Genet 87: 743–756.
14. Bar J, Bricc F, Schmidt S, Kyndt F, Le Cunff M, et al. (2011) Screening for copy number variation in genes associated with the long QT syndrome: clinical relevance. J Am Coll Cardiol 57: 40–47.
15. Bentham J, Bhattacharya S (2008) Genetic mechanisms controlling cardiovascular development. Ann N Y Acad Sci 1125: 10–19.
16. Arrington CB, Bleby SB, Matsumani N, Bonnell GD, Oterrud BE, et al. (2012) Exome analysis of a family with pleiotropic congenital heart disease. Circ Cardiovasc Genet 5: 175–182.
17. Fahed AC, Grøb BD, Seidman JG, Seidman CE (2013) Genetics of congenital heart disease: the glass half empty. Circ Res 112: 707–720.
18. Andersen TA, Troelsen KD, Larsen LA (2014) Of mice and men: molecular genetics of congenital heart disease. Cell Mol Life Sci 71:1327–52.
19. Lei YP, Zhang T, Li H, Wu BL, Jin L, et al. (2010) Vascular endothelial growth factor receptor-2 (VEGFR-2) mutation in human cranial neural-tube defects. N Engl J Med 362: 2232–2235.
20. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, et al. (2011) Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol 29: 512–520.
21. Thiengo B, Bertus L, de Ravel T, Eykens B, Bobb hoff D, et al. (2007) Submicroscopic chromosomal imbalances detected by array-CGH are a frequent cause of congenital heart defects in selected patients. Eur Heart J 28: 2776–2784.
22. Grøb BD (2013) Recent advances in understanding the genetics of congenital heart defects. Curr Opin Pediatr In press.
23. van Beynum IM, Kapusta L, den Heijer M, Vermeulen SH, Kouwenberg M, et al. (2006) Maternal MTHFR 677C>T is a risk factor for congenital heart defects: effect modification by periconceptional folic acid supplementation. Eur Heart J 27: 981–987.
24. Tang LS, Wlodarczyk BJ, Samulion DR, Miranda RC, Fennell RH (2004) Developmental consequences of abnormal folate transport during murine heart morphogenesis. Birth Defects Res A Clin Mol Teratol 70: 449–458.
25. Goldmuntz E, Woyciechowski S, Remstrom D, Lupo JP, Mitchell LE (2008) Variants of folate metabolism genes and the risk of congenital cardiac defects. Circ Cardiovasc Genet 1: 126–132.
26. Locke AE, Dooley KJ, Tinker SW, Cheong SY, Frigold E, et al. (2010) Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down syndrome. Genet Epidemiol 34: 613–623.
27. Tibbetts AS, Appel DR (2010) Compartmentalization of NGL2 mutations in Mammalian folate-mediated one-carbon metabolism. Am J Hum Genet 83: 57–81.
28. Stover PJ, Field MS (2011) Trafficking of intracellular folates. Adv Nutr 2: 325–329.
29. Thienpont B, Mertens L, de Ravel T, Eykens B, Bobbhoff D, et al. (2007) Submicroscopic chromosomal imbalances detected by array-CGH are a frequent cause of congenital heart defects in selected patients. Eur Heart J 28: 2776–2784.
33. Kozyraki R (2001) Cubilin, a multifunctional epithelial receptor: an overview. J Mol Med (Berl) 79: 161–167.

34. Tsaroucha AK, Chatzaki E, Lambropoulou M, Despoudi K, Laiouidi P, et al. (2008) Megalin and cubilin in the human gallbladder epithelium. Clin Exp Med 8: 165–170.

35. Tremblay N, Yang SW, Hitz MP, Asselin G, Ginnis J, et al. (2011) Familial ventricular aneurysms and septal defects map to chromosome 10p15. Eur Heart J 32: 568–573.

36. Pannu H, Tran-Fadulu V, Papke CL, Scherer S, Liu Y, et al. (2007) MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet 16: 2453–2462.

37. Song K, Backs J, McAnally J, Qi X, Gerard RD, et al. (2006) The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 125: 453–466.

38. Krepsi-Santos AC, Rajan D, Temple IK, Shrubh V, Croilla JA, et al. (2009) Constitutional haploinsufficiency of tumor suppressor genes in mentally retarded patients with microdeletions in 17p13.1. Cytogenet Genome Res 125: 1–7.

39. Lalani SR, Shaw C, Wang X, Patel A, Patterson LW, et al. (2013) Rare DNA copy number variants in cardiovascular malformations with extracardiac abnormalities. Eur J Hum Genet 21: 173–181.

40. Roos L, Jonch AE, Kjaergaard S, Taudorf K, Simonsen H, et al. (2009) A new microduplication syndrome encompassing the region of the Miller-Dieker (17p13 deletion) syndrome. J Med Genet 46: 703–710.

41. Gueant Rodriguez RM, Spada R, Pooya S, Jeannesson E, Moreno Garcia MA, et al. (2012) Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int J Cardiol 167:768–75.